Skip to main content

20 Years Of Helping Australians To Make The Best Decisions About Medicines And Medical Tests

Log in

Sign up

Don't miss out on the latest news, evidence and CPD opportunities on medicines and medical tests - sign up today.

My account

Log in details

My subscriptions

Add subscriptions

My favourites

Difficult-to-treat and severe asthma: changing the paradigm

WEBINAR

Tuesday, 1 May 2018 (World Asthma Day)
7:00 – 8:00 pm AEST

Register now

About the webinar

A significant group of people with asthma still have uncontrolled asthma and experience poor outcomes despite high-dose standard therapy. However, recent advances offer hope for improving these outcomes.

Join our webinar for a multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma. Our expert panel will discuss:

  • the management of asthma in adults that remains uncontrolled despite treatment with high-dose therapies
  • standardisation of asthma definitions and new evidence-based guidelines
  • advances in the use of targeted, biologic therapies
  • how a systematic and multidisciplinary approach can improve health outcomes in people with difficult-to-treat asthma.

Meet the panel

Drawing upon their extensive and diverse experiences, our panel will discuss the challenges of managing difficult-to-treat and severe asthma.

Professor Helen Reddel


Helen is a Research Leader at the Woolcock Institute of Medical Research, University of Sydney. She is Chair of the Science Committee of the Global Initiative for Asthma (GINA), a member of the Guidelines Committee for the Australian Asthma Handbook, clinical adviser to the Australian Centre for Airways Disease Monitoring (ACAM), and Visiting Professor at the China-Japan Friendship Hospital, Peking University, Beijing.



Dr H. John Fardy


John has vast experience in rural and regional medicine. He is the Regional Hospital Academic Leader and Clinical Professor with the University of Wollongong's Graduate School of Medicine. An interest in respiratory disease in primary care has led to John sitting on the National Asthma Council’s GP Asthma Group and the Lung Foundation Australia GP Asthma Group as well as Co-President of the International Primary care Respiratory Group (2002-2004).  

Dr Juliet Foster


A photograph of Dr Juliet Foster

Juliet is a Research Psychologist with a special interest in the disease beliefs, treatment attitudes and lived experience of people with asthma, COPD and cystic fibrosis. She is an experienced crisis counsellor and a training specialist in health communication skills for facilitating disease self-management. Dr Foster is outgoing convener for the Primary Care Special Interest Group for the Thoracic Society of Australia and New Zealand (TSANZ) and serves on the scientific and education committees of the European Society for Patient Adherence, Compliance and Persistence.

Lesley Vining


A photograph of Lesley Vinning
  

Lesley has over 42 years’ experience in nursing and is a nurse expert in asthma. She is a Clinical Nurse Specialist and Asthma Coordinator for Wollongong Hospital and the Illawarra region, and is involved in the Respiratory Support Community. Lesley also works with Asthma Australia to provide clinical support to practice nurses involved in research projects.

CPD

For general practitioners

Accredited by RACGP for 2 Category 2 points

This activity has been accredited for 2 (Category 2) points in the RACGP QI & CPD Program for the 2017 – 2019 triennium (activity number 127476).


    RACGP accreddited         


            


ACRRM accreditation pending

For pharmasicts and nurses

Self-recorded CPD

It is recommended that 1 CPD hour be recorded for the purposes of self-directed CPD.


Learning outcomes

Participation in this activity will help you:

  • Identify patients with difficult-to-treat asthma.
  • Assess and manage factors that contribute to poor asthma control, including inhaler technique, adherence, comorbidities and triggers.
  • Identify patient characteristics for severe, high-risk and uncontrolled asthma who may benefit from timely referral to a specialist.
  • Describe the role of biologic therapies in severe asthma and the rationale for their use.
  • Describe how a multidisciplinary and systematic approach to patients with difficult-to-treat asthma can improve patient outcomes.
VentureWise - Part of the MedicineWise Group logo

This program is joint-funded by AstraZeneca Pty Ltd and Novartis Pharmaceuticals Australia Pty Ltd and managed by VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The content has been designed, developed and delivered by NPS MedicineWise with complete independence and editorial control, based on best practice guidelines.

Key dates

Registration open

Registrations close midnight

Live webinar 7pm EST


Date published: 19 March 2018
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.